Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetes-related traits in UK samples

Diabetic Medicine

Volumn 22, Issue 12, 2005, Pages 1696-1700

  Zeggini, E ^a,b   Parkinson, J R C ^c   Halford, S ^c   Owen, K R ^a,d   Walker, M ^e   Hitman, G A ^f   Levy, J C ^g   Sampson, M J ^g   Frayling, T M ^d   Hattersley, A T ^d   McCarthy, M I ^a,b,c,h  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d PENINSULA MEDICAL SCHOOL   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^h CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Association; Body mass index; Peroxisome proliferator activated receptor 2

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC OBESITY; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST HIP RATIO;

AGE OF ONSET; ALANINE; AMINO ACID SUBSTITUTION; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 30044432152     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01717.x     Document Type: Article

References (23)

1. McCarthy MI. Progress in defining the molecular basis of type 2 diabetes through susceptibility gene identification. Hum Mol Genet 2004; 13: R33-R41.
2. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
3. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P et al. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 2001; 50: 886-890.
4. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM. Peroxisome proliferator-activated receptor-γ2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000; 85: 2014-2019.
5. Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 2004; 47: 555-558.
6. Evans D, de Heer J, Hagemann C, Wendt D, Wolf A, Beisiegel U et al. Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor γ (PPARγ) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 2001; 109: 151-154.
7. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H et al. The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271: 212-216.
8. Memisoglu A, Hu FB, Hankinson SE, Liu S, Meigs JB, Altshuler DM et al. Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARγ gene and type 2 diabetes. Diabetes Care 2003; 26: 2915-2917.
9. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J et al. The Pro12 → Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50: 891-894.
10. Nemoto M, Sasaki T, Deeb SS, Fujimoto WY, Tajima N. Differential effect of PPARγ2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans. Diabetes Res Clin Pract 2002; 57: 131-137.
11. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177-182.
12. Masud S, Ye S, SAS Group. Effect of the peroxisome proliferator activated receptor-γ gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003; 40: 773-780.
13. Frayling TM, Wiltshire S, Hitman GA, Walker M, Levy JC, Sampson M et al. Young-onset type 2 diabetes families are the major contributors to genetic loci in the Diabetes UK Warren 2 genome scan and identify putative novel loci on chromosomes 8q21, 21q22 and 22q11. Diabetes 2003; 57: 1857-1863.
14. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M et al. A genome-wide scan for loci predisposing to type 2 diabetes in a UK population (The Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 2001; 69: 553-569.
15. Frayling TM, Walker M, McCarthy MI, Evans JC, Ayres S, Allen LI et al. Parent-offspring trios: a resource to facilitate the identification of type 2 diabetes genes. Diabetes 1999; 48: 2475-2479.
16. Minton J, Hattersley AT, Owen KR, McCarthy MI, Walker M, Barrett T et al. Association studies of genetic variation in the WFS1 gene and type 2 diabetes in UK populations. Diabetes 2002; 51: 1287-1290.
17. Page GP, George V, Page PZ, Allison DB. 'Are we there yet?': deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet 2003; 73: 711-719.
18. Wang WYS, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6: 109-118.
19. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892-895.
20. Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M et al. Haplotype analysis of the PPARγPro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 2002; 3: 21.
21. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115: 42S-48S.
22. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J Clin Invest 2000; 105: 287-292.
23. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.